News|Articles|September 7, 2025

Top 5 Infectious Disease News Stories Week of August 30 to September 6

Author(s)Sophia Abene

From COVID-19 antivirals to RSV, influenza, malaria, and gram-negative infections, new research highlights both advances and ongoing challenges in infectious disease prevention and treatment.

The US Food and Drug Administration (FDA) has accepted Shionogi’s new drug application for ensitrelvir, an investigational oral antiviral for the prevention of COVID-19 following exposure, with a Prescription Drug User Fee Act decision expected by June 16, 2026. The application is supported by phase 3 SCORPIO-PEP trial results, which demonstrated a 67% relative risk reduction in symptomatic COVID-19 compared with placebo (2.9% vs 9%; risk ratio, .33; 95% CI, .22-0.49; P < .0001), with consistent findings across broader analyses. Ensitrelvir, a SARS-CoV-2 main protease inhibitor marketed as Xocova in Japan and Singapore, was well tolerated with adverse events comparable to placebo and is also under regulatory review in Europe, Taiwan, and other regions. If approved, it would be the first oral antiviral available in the United States for postexposure prophylaxis of COVID-19.

Related to this article

FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.